CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
Navigating private equity in health care amid regulatory scrutiny
She joined Leslie C. Overton from Axinn Veltrop & Harkrider LLP and Rebekah Goshorn Jurata of the American Investment Council to discuss the growing antitrust...